Long-Term Assets: The sum of all assets classified as non-current.
Sino Biopharmaceutical (SBMFF) had Long-Term Assets of $5.73B for the most recently reported fiscal quarter, ending 2024-06-30.
Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
Balance Sheet Financials | |
$3.48B |
|
$1.11B |
|
Long-Term Assets |
$5.73B |
$9.21B |
|
$3.03B |
|
$139.48M |
|
$363.60M |
|
$3.39B |
|
$5.82B |
|
$5.39B |
|
$5.82B |
|
18.79B |
|
Cash Flow Statement Financials | |
$425.14M |
|
$-281.85M |
|
$-566.14M |
|
$1.04B |
|
$617.23M |
|
$-419.22M |
|
-- |
|
$-122.80M |
|
-- |
|
Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |